COLOPHON -- PANEL No.8
About TB-500 Meds.
What this project is, what it is not, and why a comic page is the right form for a research record built from quotable facts.
What TB-500 Meds is
TB-500 Meds keeps a card catalog of the published research on Thymosin Beta-4 and its Ac-LKKTETQ fragment: one card per finding, each stating what a study showed and carrying its citation. It is a catalog to read, not a counter to buy from. Despite the name, nothing here is sold, supplied, dispensed, or dosed, no prescription is filled, no appointment is taken, and no clinical staff is kept. No page offers medical guidance or a human dose. What the catalog provides is a cited, browsable account of what the literature reports.
What the name does and does not claim
'Meds' is shorthand for the subject filed here — the research on a peptide often discussed as a medicine — not a claim that the site supplies one. The catalog names no product, endorses no source, and promises no remedy. Its cards distinguish what is established from what is asserted: mechanism versus outcome, animal data versus human evidence, marketing versus the primary record. That line is drawn openly so the name is never read as a storefront.
How we work
Every card is sourced. A quantitative claim is filed only with a specific peer-reviewed study, registered trial, or regulatory document behind it, and each reference is checkable. Failed and negative results are filed beside the favorable ones, and vendor copy that conflates the synthetic fragment with full-length Tβ4 is corrected. No seller is linked; the catalog cross-references only PubMed, ClinicalTrials.gov, the NIH, journal pages, and the agencies of record.